ReviewResearch (Washington, D.C.)2026
Pathogenesis of Micro/Nanoplastics in Mammalian Systems: Gut to Systemic Multi-Organ Dysfunction.
Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Micro- and nanoplastics (MNPs) have emerged as widespread environmental contaminants with growing implications for human health. Growing evidence indicates that the gastrointestinal tract is not only the primary site of exposure but also a central regulator of systemic toxicity through interactions among the intestinal barrier, immune system, and gut microbiota. Consequently, research has shifted from describing tissue accumulation to elucidating how intestinal dysfunction drives multi-organ effects via the gut-organ axis. This review summarizes recent advances in mechanisms by which ingested MNPs disrupt intestinal homeostasis and subsequently affect extraintestinal organs. We first examine how particle size, morphology, surface properties, environmental weathering, and polymer chemistry shape intestinal responses. Particular attention is given to the emerging view that biodegradable plastics, despite lower environmental persistence, may produce bioactive degradation products in the gastrointestinal tract that alter host-microbiota metabolism. We then integrate current evidence on how barrier disruption, microbial dysbiosis, altered microbial metabolites, and immune signaling mediate communication along the gut-liver, gut-brain, gut-lung, and gut-endocrine axes. In addition, we compare commonly used experimental models, highlighting their respective strengths and limitations for mechanistic studies and translational research. Finally, we discuss intervention strategies and key challenges, including environmentally realistic exposure assessment, methodological standardization, long-term biological adaptation, and the development of human-relevant models. Overall, MNP toxicity arises from dynamic interactions between particle properties and host responses rather than burden alone. Ultimately, MNP risk assessment should move beyond the "particle-accumulation" paradigm toward a "systemic-disruption" framework, where the gut is recognized as a biological amplifier of exposure and functional homeostasis takes precedence over particle burden.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.